SCHEMBL3976942

SCHEMBL3976942

COc1c(OCc2ccccc2)ccc(C(=O)OC(=O)c2occ(-c3ccccc3)c2-c2ccccc2)c1C(=O)NN

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.37
ALDH1A1 P00352 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MGAM O43451 3/20 0.37
GAA P10253 3/20 0.37
SI P14410 3/20 0.37
MGAM2 Q2M2H8 3/20 0.37
SMPD1 P17405 2/20 0.36
PIN1 Q13526 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
CYP3A4 P08684 1/20 0.35
HPGD P15428 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3978639 0.91 HTT (0.37) MAPTALDH1A1KDM4EGAANPC1
SCHEMBL3977753 0.86 PDE4B (0.35) MAPTALDH1A1MGAMGAASI
SCHEMBL3974632 0.85 CTSD (0.38) MAPTALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL3978027 0.84 CTSD (0.37) MAPTALDH1A1KDM4EHPGD
SCHEMBL3974207 0.84 ACLY (0.37) MAPTALDH1A1KDM4EHDAC8L3MBTL1
SCHEMBL3977002 0.83 POLB (0.37) MAPTALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL3982340 0.83 CTSD (0.36) MAPTALDH1A1KDM4E
SCHEMBL3979544 0.81 HPGD (0.41) MAPTALDH1A1KDM4EGAAHPGD
SCHEMBL3980558 0.81 POLB (0.38) ALDH1A1KDM4EHPGDTDP1L3MBTL1
SCHEMBL3978783 0.81 S1PR1 (0.35) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 MAPT 4833/4885ALDH1A1 1389/4885KDM4E 2769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.